AlloMap^®

Provides a non-invasive method to aid in the management of heart transplant rejection.

Find out more about the completed IMAGE study.

What's new?

XDx Announces Positive Results from European CARGO II Study of AlloMap^® Expression Testing

XDx: The Company Behind AlloMap^®, a non-invasive gene expression test to aid in Heart Transplant Management

XDx is a molecular diagnostics company focused on the discovery, development and commercialization of non-invasive gene expression testing in the areas of transplant medicine and autoimmunity. The company has developed a proprietary method of utilizing gene expression in blood that provides a new tool for physicians to manage the care of heart transplant patients.

The molecular expression technology developed and implemented by XDx in heart transplant patient management is currently being explored to assist with other diseases that involve the immune system.

Update

Results from the Invasive Monitoring Attenuation through Gene Expression (IMAGE) Study were presented at ISHLT on Thursday, April 22, 2010. This comparative effectiveness research study was designed to demonstrate the non-inferiority of clinical outcomes of heart transplant recipients managed with the AlloMap test compared with conventional endomyocardial biopsy.